AZD9164

AZD9164

Identifiers
IUPAC name [(3R)-1-[2-(4-fluorophenyl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2S)-2-phenyl-2-piperidin-1-ylpropanoate
CAS Number	(free azonium ion) 1034978-04-5 (free azonium ion) 1034916-72-7 (bromide salt)
PubChem CID	44517831
DrugBank	DB12115
ChemSpider	28481905
UNII	977LWC4O5D
ChEMBL	ChEMBL1921904
Chemical and physical data
Formula	C29H38FN2O2
Molar mass	465.633 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@](C1=CC=CC=C1)(C(=O)O[C@H]2C[N+]3(CCC2CC3)CCC4=CC=C(C=C4)F)N5CCCCC5
InChI InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1 Key:FNYFFCOCVNTJCD-NNMXADRKSA-N

AZD9164 is an experimental drug that acts as a potent and selective antagonist of the Muscarinic acetylcholine receptor M3. It contains a quaternary nitrogen atom with a permanent positive charge and so is always encountered as a salt, usually paired with a bromide. It has been investigated for the treatment of Chronic obstructive pulmonary disease (COPD) and reached phase II human clinical trials but did not progress to further development, however it is still used for research into the M3 receptor and its function. ^{[1] [2] [3]}

References

1. Mete A, Bowers K, Chevalier E, Donald DK, Edwards H, Escott KJ, et al. (December 2011). "The discovery of AZD9164, a novel muscarinic M3 antagonist". Bioorganic & Medicinal Chemistry Letters. 21 (24): 7440–7446. doi:10.1016/j.bmcl.2011.10.002. PMID   22047691.
2. Bjermer L, Bengtsson T, Jorup C, Lötvall J (January 2013). "Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD". Respiratory Medicine. 107 (1): 84–90. doi:10.1016/j.rmed.2012.09.014. PMID   23098686.
3. Mastrodicasa MA, Droege CA, Mulhall AM, Ernst NE, Panos RJ, Zafar MA (February 2017). "Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs". Expert Opinion on Investigational Drugs. 26 (2): 161–174. doi:10.1080/13543784.2017.1276167. PMID   28004591.